- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07660224
The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Thalassemia (MITAS)
The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Beta-Thalassemia Major
Beta-thalassemia major is a chronic hereditary blood disorder that requires lifelong treatment, including regular blood transfusions and iron chelation therapy. Poor adherence to treatment remains a significant challenge and may lead to iron overload and related complications. Self-efficacy is an important factor influencing patients' ability to adhere to treatment recommendations.
This study aims to evaluate the effect of nurse-delivered Motivational Interviewing (MI) on treatment adherence and self-efficacy among Omani adults with beta-thalassemia major. A pre-experimental one-group repeated-measures design will be used. Approximately 45 participants will be recruited from the Oman National Center for Hematology and Bone Marrow Transplantation and Royal Hospital in Muscat, Oman.
Participants will receive three individualized MI sessions over a period of six to eight weeks. Treatment adherence and self-efficacy will be assessed at baseline, immediately after completion of the intervention, and at three-month follow-up. Secondary outcomes include serum ferritin level and frequency of thalassemia-related hospital admissions. The findings will provide evidence regarding the usefulness of motivational interviewing in improving adherence-related outcomes among adults with beta-thalassemia major.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Beta-thalassemia major is a lifelong transfusion-dependent condition that requires continuous adherence to iron chelation therapy to prevent iron overload and its associated complications. Despite advances in treatment, suboptimal adherence remains common among adults with beta-thalassemia major and contributes to increased morbidity and healthcare utilization. Self-efficacy has been identified as a key determinant of adherence behavior and may be enhanced through behavioral interventions.
This study will evaluate the effectiveness of a nurse-delivered Motivational Interviewing (MI) intervention on treatment adherence and self-efficacy among Omani adults with beta-thalassemia major. The study is guided by Social Cognitive Theory and uses a quantitative pre-experimental one-group repeated-measures design.
Eligible participants will be adults aged 18 years and older with beta-thalassemia major who are receiving regular follow-up and iron chelation therapy. Participants will be recruited from the Oman National Center for Hematology and Bone Marrow Transplantation, University Medical City, and Royal Hospital in Muscat, Oman.
The intervention consists of three individual motivational interviewing sessions delivered by a trained nurse over six to eight weeks. Each session will last approximately 30 minutes and will focus on exploring treatment-related challenges, enhancing motivation, strengthening self-efficacy, and supporting adherence to iron chelation therapy.
Primary outcomes include treatment adherence measured using the Arabic version of the Adherence to Refills and Medications Scale (ARMS) and self-efficacy measured using the Arabic version of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS). Assessments will be conducted at baseline, immediately after the intervention, and three months after completion of the intervention.
Secondary outcomes include changes in serum ferritin levels and thalassemia-related hospital admission frequency. Data will be analyzed using descriptive statistics and repeated-measures statistical tests to examine changes across study time points.
The results of this study may support the integration of motivational interviewing into routine nursing practice for adults with beta-thalassemia major and contribute to improving patient-centered chronic disease management in Oman.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Mizna Said Al-sinani, RN, BSN
- Telefonnummer: 968-99851427
- E-mail: s100722@student.squ.edu.om
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Adults aged 18 years and older.
- Diagnosed with transfusion-dependent beta-thalassemia major.
- Receiving iron chelation therapy for at least 6 months.
- Receiving regular follow-up at the participating study sites.
- Able to communicate in Arabic or English.
- Willing and able to provide informed consent.
- Able to attend the motivational interviewing sessions and complete study questionnaires.
Exclusion Criteria:
- Current hospitalization for an acute medical condition at the time of recruitment.
- Severe cognitive impairment or psychiatric illness that may affect participation.
- Participation in another structured psychosocial or behavioral intervention program.
- Unable or unwilling to provide informed consent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Motivational Interviewing Intervention
Participants will receive three individual motivational interviewing sessions delivered by a trained nurse over six to eight weeks.
Each session will last approximately 30 minutes and will focus on enhancing treatment adherence, addressing barriers to iron chelation therapy, strengthening self-efficacy, and supporting self-management behaviors.
|
Motivational Interviewing is a patient-centered behavioral intervention designed to enhance intrinsic motivation for behavior change.
Participants will receive three individualized sessions over six to eight weeks focusing on treatment adherence, self-efficacy, goal setting, and management of barriers related to iron chelation therapy.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment Adherence
Tidsramme: Baseline, post-intervention (after completion of the third motivational interviewing session), and 3-month follow-up
|
Treatment adherence measured using the Arabic version of the Adherence to Refills and Medications Scale (ARMS).
|
Baseline, post-intervention (after completion of the third motivational interviewing session), and 3-month follow-up
|
|
Self-Efficacy
Tidsramme: Baseline, post-intervention (after completion of the third motivational interviewing session), and 3-month follow-up
|
Self-efficacy measured using the Arabic version of the Self-Efficacy for Appropriate Medication Use Scale (SEAMS).
|
Baseline, post-intervention (after completion of the third motivational interviewing session), and 3-month follow-up
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum Ferritin Level
Tidsramme: Baseline and 3-month follow-up
|
Change in serum ferritin level following the motivational interviewing intervention.
|
Baseline and 3-month follow-up
|
|
Hospital Admission Frequency
Tidsramme: Three months before intervention compared with three months after intervention
|
Number of thalassemia-related hospital admissions before and after the intervention.
|
Three months before intervention compared with three months after intervention
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Mizna Said Al-sinani, RN,BSN, Sultan Qaboos University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Genetiske sygdomme, medfødte
- Hæmatologiske sygdomme
- Anæmi, hæmolytisk, medfødt
- Anæmi, hæmolytisk
- Anæmi
- Hæmoglobinopatier
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Opførsel
- Hemiske og lymfatiske sygdomme
- Sundhedsadfærd
- Thalassæmi
- beta-thalassæmi
- Behandlingsoverholdelse og compliance
- Sundhedstjenester
- Sundhedsfaciliteter Arbejdsstyrke og tjenester
- Adfærdsdiscipliner og aktiviteter
- Direktivrådgivning
- Rådgivning
- Mental sundhedsydelser
- Motiverende interviews
Andre undersøgelses-id-numre
- MoH/CSR/26/32221
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Beta-thalassæmi major
-
Ataturk UniversityIkke rekrutterer endnuBeta-thalassæmi major | Thalassemia Majors (Beta-Thalassemi Major)Kalkun
-
Guangzhou Women and Children's Medical CenterRekrutteringThalassemia Majors (Beta-Thalassemi Major) | Haplo-identiske donorerKina
-
Assiut UniversityIkke rekrutterer endnuThalassemia Majors (Beta-Thalassemi Major)
-
Sohag UniversityIkke rekrutterer endnuThalassemia Majors (Beta-Thalassemi Major)
-
Hamad Medical CorporationAfsluttetOsteoporose | Thalassemia Majors (Beta-Thalassemi Major)Qatar
-
Hospital Universitari Vall d'Hebron Research InstituteHospital General Universitario Gregorio Marañon; Universitaire Ziekenhuizen... og andre samarbejdspartnereAfsluttetSeglcellesygdom | Hæmoglobinopatier | Seglcelleanæmi | Beta-thalassæmi | Segl Beta Thalassæmi | Alfa-thalassæmi | Beta Thalassæmi Intermedia | Beta-thalassæmi major | Sfærocytose, arvelig | Seglcellehæmoglobin C | Elliptocytose, arvelig | Stomatocytose | Sickle-cell; Hemoglobinopati | Sickle Cell Hemoglobin D | Sickle Cell-Hemoglobin... og andre forholdSpanien
-
UCSF Benioff Children's Hospital OaklandNovartis PharmaceuticalsAfsluttet
-
Regeneron PharmaceuticalsRekrutteringIkke-transfusionsafhængig beta-thalassemia (NTDT)Forenede Stater, Thailand, Det Forenede Kongerige, Malaysia, Grækenland, Indien, Georgien, Italien, Tyrkiet (Türkiye)
-
CelgeneAfsluttetBeta Thalassæmi Intermedia | Beta-thalassæmi majorFrankrig, Det Forenede Kongerige, Italien, Grækenland
-
M.D. Anderson Cancer CenterTrukket tilbageSeglcellesygdom | Segl Beta Thalassæmi | Beta-thalassæmi major | Seglcelle-SS sygdom | Segl Beta 0 Thalassæmi | Segl Beta Plus ThalassæmiForenede Stater
Kliniske forsøg med Motivational Interviewing
-
Wright State UniversityPremier HealthIkke rekrutterer endnuUdbrændthed, professionel | Patientengagement | Motiverende samtale | Flere kroniske tilstande | Implicit biasForenede Stater
-
Universiti Sains MalaysiaIkke rekrutterer endnuSunde kvinder | Caries af spædbørn
-
Northwell HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA)AfsluttetAlkohol drikke | Alkoholisme | Alkohol-relaterede lidelser | Alkoholbrugsforstyrrelser | Alkohol misbrugForenede Stater
-
University of VermontAfrica Mental Health FoundationAfsluttetAlkoholbrugsforstyrrelse
-
University of MiamiAB InBev FoundationAfsluttet
-
Florida State UniversityJohns Hopkins University; Children's Hospital of Philadelphia; University... og andre samarbejdspartnereAfsluttetHIV-infektioner | Ungdomsudvikling | Plejefremkaldende adfærd | Patient manglende overholdelse | Patient afslag på behandlingForenede Stater
-
Yale UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RekrutteringAlkohol drikke | Hiv | Efterår | Brug af cannabisForenede Stater
-
Penn Medicine Princeton HealthUkendtVægttabForenede Stater
-
The Cleveland ClinicAmerican Academy of Sleep MedicineAfsluttetObstruktiv søvnapnø | Akut dekompenseret hjertesvigt | Motiverende forbedring | PAP OverholdelseForenede Stater
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...Afsluttet